BridgeBio Oncology Therapeutics (BBOT) officer has 1,047 shares withheld for RSU tax

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. Chief Med & Dev Officer Ben Yong reported a routine tax-related share disposition. On April 1, 2026, 1,047 shares of Common Stock were withheld by the company at $9.03 per share to cover his tax obligations upon vesting of restricted stock units. After this withholding, Yong directly holds 45,623 shares of the company’s Common Stock, indicating he retains the vast majority of his equity position and that the transaction was not an open-market sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ben Yong

Role Chief Med & Dev Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	1,047	$9.03	$9K

Holdings After Transaction: Common Stock — 45,623 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares withheld for taxes: 1,047 shares Withholding share value: $9.03 per share Shares held after transaction: 45,623 shares

3 metrics

Shares withheld for taxes 1,047 shares Common Stock withheld on April 1, 2026 for tax obligations

Withholding share value $9.03 per share Reported price per share for withheld Common Stock

Shares held after transaction 45,623 shares Direct Common Stock ownership following tax withholding

Key Terms

restricted stock units, tax withholding obligations, Form 4

3 terms

restricted stock units financial

"in connection with the vesting of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations"

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ben Yong

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Med & Dev Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		F		1,047(1)	D	$9.03	45,623	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.

	/s/ Aaron Chan, Attorney-in-Fact	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did BBOT executive Ben Yong report on this Form 4?

Ben Yong reported a tax-related share disposition, not an open-market trade. On April 1, 2026, 1,047 BridgeBio Oncology Therapeutics common shares were withheld by the company to satisfy his tax obligations upon vesting of restricted stock units.

Did Ben Yong sell BridgeBio Oncology Therapeutics (BBOT) shares on the open market?

No, he did not sell shares on the open market. The 1,047 BBOT shares were withheld by the issuer to cover tax withholding obligations related to restricted stock unit vesting, a standard non-cash administrative transaction.

How many BBOT shares were withheld for Ben Yong’s tax obligations?

A total of 1,047 shares of BridgeBio Oncology Therapeutics common stock were withheld. The company applied these shares, valued at $9.03 per share, to meet Ben Yong’s tax liabilities arising from the vesting of restricted stock units.

What is Ben Yong’s BridgeBio Oncology Therapeutics shareholding after this transaction?

Following the tax-withholding transaction, Ben Yong directly holds 45,623 shares of BridgeBio Oncology Therapeutics common stock. This post-transaction balance shows he maintains a substantial equity stake despite the routine shares withheld for taxes.

What does transaction code "F" mean on this BBOT Form 4 filing?

Transaction code “F” indicates a tax-withholding disposition. In this BBOT filing, it shows shares were delivered back to the issuer to satisfy tax obligations connected with restricted stock unit vesting, rather than being sold in the market.

At what price were the withheld BBOT shares valued in Ben Yong’s Form 4?

The 1,047 withheld BridgeBio Oncology Therapeutics shares were valued at $9.03 per share. This price is used solely for reporting the value of shares applied toward Ben Yong’s tax withholding obligations tied to restricted stock unit vesting.